Company profile for NS Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At NS Pharma we believe in the potential of new therapies, such as our exon-skipping technology for DMD, to redefine the way patients and healthcare providers fight rare diseases. We take pride in our drive for future innovation and commitment to helping patients live healthier, happier lives. We recognize the urgent unmet need of those affected by rare diseases like DMD and are committed to fulfilling the promise of exon-skip...
At NS Pharma we believe in the potential of new therapies, such as our exon-skipping technology for DMD, to redefine the way patients and healthcare providers fight rare diseases. We take pride in our drive for future innovation and commitment to helping patients live healthier, happier lives. We recognize the urgent unmet need of those affected by rare diseases like DMD and are committed to fulfilling the promise of exon-skipping technology. We aim to offer healthier futures to more patients by: Conducting rigorous clinical research to continue validating patient outcomes with comprehensive endpoints.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
140 East Ridgewood Ave, Suite 280S Paramus, NJ 07652
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/brogidirsen-ns-089ncnp-02-3-5-year-clinical-trial-data-for-the-treatment-of-duchenne-muscular-dystrophy-presented-at-2025-world-muscle-society-congress-302580951.html

PR NEWSWIRE
14 Oct 2025

https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-ns-051ncnp-04--for-the-treatment-of-duchenne-muscular-dystrophy-302560287.html

PR NEWSWIRE
19 Sep 2025

https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-302550236.html

PR NEWSWIRE
09 Sep 2025

https://www.prnewswire.com/news-releases/ns-pharma-announces-strategic-alliance-with-boston-childrens-hospital-to-develop-new-therapies-for-rare-diseases-302494701.html

PR NEWSWIRE
01 Jul 2025

https://www.prnewswire.com/news-releases/fda-accepts-biologics-license-application-for-mucopolysaccharidosis-ii-treatment-302454515.html

PR NEWSWIRE
14 May 2025

https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-302431734.html

PR NEWSWIRE
21 Apr 2025

ABOUT THIS PAGE

Contact NS Pharma and get a quotation

NS Pharma is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of Ilginatinib bulk offered by NS Pharma

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty